• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Ethos Technologies Inc.

    2/2/26 7:02:49 AM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    8-K
    --12-31 false 0001788451 0001788451 2026-01-28 2026-01-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 28, 2026

     

     

    ETHOS TECHNOLOGIES INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-43065   81-3181024

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    90 New Montgomery Street, Suite 1500  
    San Francisco, CA   94105
    (Address of Principal Executive Offices)   (Zip Code)

    (415) 915-0665

    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A Common Stock, $0.0001 par value   LIFE   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01 Entry into a Material Definitive Agreement

    Exchange Agreements

    On January 28, 2026, in connection with its initial public offering (the “IPO”), Ethos Technologies Inc. (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with Peter Colis and Lingke Wang, (each a “Co-Founder,” and together, the “Co-Founders”) who are both current executive officers and directors of the Company, and their respective affiliates, and entities affiliated with Accel and Sequoia Capital, the Company’s two largest stockholders. The Exchange Agreements provide for the exchange of shares of Class A common stock for shares of Class B common stock, effective immediately prior to the sale of the shares of the Company’s Class A common stock at the closing of the IPO. The Exchange Agreements are attached hereto as Exhibits 10.1 and 10.2 and are incorporated herein by reference.

    Equity Exchange Right Agreements

    On January 28, 2026, in connection with the IPO, the Company entered into equity exchange right agreements (each an “Equity Exchange Right Agreement”) with each of the Co-Founders. Each Equity Exchange Right Agreement requires the Company to exchange any shares of Class A common stock received upon the vesting and settlement of restricted stock units related to shares of Class A common stock or upon the exercise of stock options to purchase shares of Class A common stock for an equivalent number of shares of Class B common stock, upon the election of each Co-Founder. The equity exchange right applies to equity awards granted to the Co-Founders prior to the IPO. The Equity Exchange Rights Agreements are attached hereto as Exhibits 10.3 and 10.4 and are incorporated herein by reference.

    Item 5.03 Amendments to Articles of Incorporation or Bylaws

    Amendment and Restatement of Certificate of Incorporation

    On January 30, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the IPO. The Company’s board of directors (the “Board”) and the Company’s stockholders previously approved the Restated Certificate to be effective upon the closing of the IPO. The Restated Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

    Amendment and Restatement of Bylaws

    On January 30, 2026, the Company’s amended and restated bylaws (the “Restated Bylaws”) became effective in connection with the closing of the IPO. The Board and the Company’s stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO. The Restated Bylaws are attached hereto as Exhibit 3.2 and are incorporated herein by reference.

    Please see the description of the Restated Certificate and the Restated Bylaws in the section titled “Description of Capital Stock” in the final prospectus filed by the Company with the Securities and Exchange Commission on January 29, 2026, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Company’s Registration Statement on Form S-1, as amended (File No. 333-290534).


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.
     

    Description

    3.1   Amended and Restated Certificate of Incorporation of Ethos Technologies Inc.
    3.2(1)   Amended and Restated Bylaws of Ethos Technologies Inc.
    10.1   Exchange Agreement among Ethos Technologies Inc., Peter Colis, Lingke Wang, and certain other affiliated parties, dated January 28, 2026.*
    10.2   Exchange Agreement among Ethos Technologies Inc., entities affiliated with Sequioa Capital and entities affiliated with Accel, dated January 28, 2026.*
    10.3   Equity Exchange Right Agreement between Ethos Technologies Inc. and Peter Colis, dated January 28, 2026*
    10.4   Equity Exchange Right Agreement between Ethos Technologies Inc. and Lingke Wang, dated January 28, 2026*.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     
    (1)

    Previously filed as Exhibit 3.4 to the Company’s Registration Statement on Form S-1, as amended (File No. 333-290534), filed with the Securities and Exchange Commission on January 20, 2026, and incorporated herein by reference.

    *

    Certain portions of this exhibit (indicated by asterisks) have been omitted because they are both not material and are the type that the Registrant treats as private or confidential.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Ethos Technologies Inc.
    Dated: February 2, 2026  
        By:  

    /s/ Peter Colis

          Peter Colis
          Chief Executive Officer
    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    SEC Form 8-K filed by Ethos Technologies Inc.

    8-K - Ethos Technologies Inc. (0001788451) (Filer)

    2/2/26 7:02:49 AM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 424B4 filed by Ethos Technologies Inc.

    424B4 - Ethos Technologies Inc. (0001788451) (Filer)

    1/29/26 9:55:44 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form S-8 filed by aTyr Pharma Inc.

    S-8 - Ethos Technologies Inc. (0001788451) (Filer)

    1/29/26 8:09:47 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Ethos Files Registration Statement for Proposed Initial Public Offering

    AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Ethos intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "LIFE." Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. BofA Securities,

    9/26/25 1:50:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives

    AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with Lifeforce, the largest longevity medicine platform. Through this collaboration, Ethos policyholders will be able to gain valuable insights into their own health at affordable prices, starting with a $250 benefit to Lifeforce's Diagnostic offering, that includes at-home biomarker testing, access to board-certified longevity physicians, personalized treatment protocols, and ongoing health coaching. Together, Ethos and Lifeforce aim to help more families safeguard their future - uniting financial protection

    8/13/25 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Softbank Group Corp. converted options into 2,697,089 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/3/26 9:00:15 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Accel Growth Fund Iv L.P. converted options into 7,143,886 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 9:08:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Sc Us (Ttgp), Ltd. returned 12,000,124 shares to the company and converted options into 12,000,124 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:41:52 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma downgraded by Oppenheimer

    Oppenheimer downgraded aTyr Pharma from Outperform to Perform

    7/5/23 7:41:57 AM ET
    $LIFE
    Specialty Insurers
    Finance

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Specialty Insurers
    Finance

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    2/28/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

    SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

    3/2/23 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance